The use of MFAT (Micro-Fragmented Adipose Tissue) Lipogems as infiltrative therapy in athletes has become an increasingly prevalent and promising treatment in recent years, both for preventing and reducing the common risks of overuse arthritis in athletes, and for muscular and joint recovery after intense training and competition seasons.
What Science Says
Numerous scientific studies have established the indications of Lipogems MFAT tissue for athletes, demonstrating that it is an innovative regenerative medicine technology effective for muscle injuries, tendon injuries, ligament injuries, arthritis, fractures, cartilage damage, and pain.
The infiltration of Lipogems tissue into injured or damaged tissue has demonstrated promotion of healing and regeneration of injured muscle, ligament, and tendon tissues in athletes. Lipogems micro-fragmented adipose tissue contains mesenchymal stem cells, growth factors, and other selected cells with high regenerative potential that can promote repair and regeneration of damaged tissue, along with anti-inflammatory properties.
In treating arthritic pain and damage, MFAT Lipogems has extensive applications in sports medicine, due to its anti-inflammatory properties and regenerative effects on cartilage damaged by arthritic disease. When properly harvested and prepared with the Lipogems system, micro-fragmented adipose tissue MFAT is infiltrated into the joint to reduce inflammation, promote cartilage healing, improve joint health and stability, and accelerate recovery following other procedures, fractures, and microfractures.
In athletes suffering from pain, such as that caused by joint or muscular conditions, the use of MFAT Lipogems has proven effective in reducing inflammation, improving limb functionality, and alleviating pain.
The results of Lipogems treatment may vary depending on individual conditions and specific athlete needs. To learn more about how Lipogems regenerative technology can help faster recovery after sports trauma, contact us for a personalized consultation.
